Abstract
Background Depression and anxiety affect 4% to 14% of Australians every year; symptoms may have been exacerbated during the COVID-19 pandemic. We examined recent patterns of antidepressant use in Australia in the period 2015 to 2021, which includes the first year of the pandemic.
Methods We used national dispensing claims for people aged ≥10 years to investigate annual trends in prevalent and new antidepressant use (no antidepressants dispensed in the year prior). We conducted stratified analyses by sex, age group and antidepressant class. We report outcomes from 2015 to 2019 and used time series analysis to quantify changes during the first year of the COVID-19 pandemic (March 2020 to February 2021).
Results In 2019 the annual prevalence of antidepressant use was 170.4 per 1,000 women and 101.8 per 1,000 men, an increase of 7.0% and 9.2% from 2015, respectively. New antidepressant use also increased for both sexes (3.0% for women and 4.9% for men) and across most age groups, particularly among adolescents (aged 10-17 years; 46%-57%). During the first year of the COVID-19 pandemic, we observed higher than expected prevalent use (+2.2%, 95%CI 0.3%, 4.2%) among females, corresponding to a predicted excess of 45,217 (95%CI 5,819, 84,614) females dispensed antidepressants. The largest increases during the first year of the pandemic occurred among female adolescents for both prevalent (+11.7%, 95%CI 4.1%, 20.5%) and new antidepressant use (+15.6%, 95%CI 8.5%, 23.7%).
Conclusion Antidepressant use continues to increase in Australia overall and especially among young people. We found a differential impact of the COVID-19 pandemic in treated depression and anxiety, greater among females than males, and greater among young females than other age groups, suggesting an increased mental health burden in populations already on a trajectory of increased use of antidepressants prior to the pandemic. Reasons for these differences require further investigation.
Competing Interest Statement
SAP is a member of the Drug Utilisation Sub Committee of the Pharmaceutical Benefits Advisory Committee. The views expressed in this paper do not represent those of the Committee. In 2020, the Centre for Big Data Research in Health, UNSW Sydney has received funding from AbbVie Australia to conduct post-market surveillance research. AbbVie did not have any knowledge of, or involvement in, the current study.
Funding Statement
This research is supported by the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence (ID: 1196900). AS is supported by an NHMRC Early Career Fellowship (#1158763). HZ is supported by a UNSW Scientia Program Award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was approved by the New South Wales Population and Health Services Research Ethics Committee (Approval number: 2013/11/494) and data access for the PBS 10% sample was granted by the Australian Government Services Australia External Request Committee (Approval number: MI7542).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: malcolm.gillies{at}unsw.edu.au
Email: andrea.schaffer{at}unsw.edu.au
Email: dpeiris{at}georgeinstitute.org
Email: h.zoega{at}unsw.edu.au
Email: sallie.pearson{at}unsw.edu.au
Funding statement: This research is supported by the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence (ID: 1196900). AS is supported by a NHMRC Early Career Fellowship (#1158763). HZ is supported by a UNSW Scientia Program Award.
Conflict of interest: SAP is a member of the Drug Utilisation Sub Committee of the Pharmaceutical Benefits Advisory Committee. The views expressed in this paper do not represent those of the Committee. In 2020, the Centre for Big Data Research in Health, UNSW Sydney has received funding from AbbVie Australia to conduct post-market surveillance research. AbbVie did not have any knowledge of, or involvement in, the current study.
Data Availability statement: Aggregate Pharmaceutical Benefits Scheme (PBS) claims data are publicly available at https://www.pbs.gov.au/info/statistics/dos-and-dop/dos-and-dop. The PBS 10% sample data were used under license from the Australian Government Services Australia. Access to these data by other individuals or authorities is not permitted without the express permission of the approving human research ethics committees and data custodians.
Data Availability
Aggregate Pharmaceutical Benefits Scheme (PBS) claims data are publicly available at https://www.pbs.gov.au/info/statistics/dos-and-dop/dos-and-dop. The PBS 10% sample data were used under license from the Australian Government Services Australia. Access to these data by other individuals or authorities is not permitted without the express permission of the approving human research ethics committees and data custodians.
